BioMarin Pharmaceuticalvs.Neurocrine Biosciences
BMRN vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Neurocrine Biosciences is about 1.5× larger than BioMarin Pharmaceutical by market cap; Neurocrine Biosciences trades at the lower P/E (26.4 vs 42.6); year to date, Neurocrine Biosciences leads (+24.9% vs −0.5%).
Side by side
| BMRN | NBIX | |
|---|---|---|
| Market cap | $11.4B | $17.7B |
| Price | $59.12 | $177.11 |
| Today | −1.4% | −1.9% |
| Return YTD | −0.5% | +24.9% |
| Return 1Y | +0.5% | +31.3% |
| P/E | 42.6 | 26.4 |
| P/S | 3.5 | 5.7 |
| P/B | 1.8 | 5.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →More comparisons in Biotech & innovation
See where BMRN and NBIX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →